Compare Quest Diagnostics Inc (DGX) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Rivian Automotive, Inc. — how do they compare? Quest Diagnostics Inc trades at $204.5 (market cap $22.80B), while Rivian Automotive, Inc. trades at $17.94 (market cap $25.33B). The key difference: Quest Diagnostics Inc and Rivian Automotive, Inc. are close in size by market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| DGX | RIVN | |
|---|---|---|
Market Cap | $22.80B | $25.33B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $22.45 |
52-Week Low | $166.42 | $11.64 |
Enterprise Value | $28.82B | $27.07B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Rivian Automotive (RIVN) trades at $17.31, down 0.97% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $19.22. The company has beaten EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -63.62%. Recent news highlights the potential of the R2 vehicle launch and a $1.74 billion stock offering to fund expansion, creating mixed investor sentiment amid growth prospects and dilution concerns.
The outlook hinges on R2 success and path to profitability, offering upside if execution improves, but high cash burn, competitive pressures, and shareholder dilution present significant risks. Analyst consensus is cautiously optimistic with 44.83% buy ratings, but the stock faces volatility around earnings and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
